Engflag

Serlain

Quick links to important sections

Serlain

Serlain_EN

Method of action: Antidepressant, Psychoanaleptics

Treatment option: Osteochondritis Dissecans, Generalized Anxiety Disorder, Clinical Depression, Obsessive Compulsive Personality Disorder, Panic, Anxiety&Panic Attacks, Panic Attacks And Panic Disorder, Post-Traumatic Stress Disorder, Premenstrual Dysphoric Disorder, Stress

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Serlain

Quick Facts

Property Description
Active ingredient Sertraline (as hydrochloride salt)
Form Film-coated tablets
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose Mood stabilization and emotional support
Origin Synthetic substance

Defining Serlain: What Type of Medicine is Sertraline?

Serlain is a psychotropic agent and a prescription-only medicine (POM), classified as a second-generation antidepressant belonging to the class of Selective Serotonin Reuptake Inhibitors (SSRIs). The core of this medicine is the active substance, Sertraline (Sertraline hydrochloride), which is a synthetic substance that acts as a key agent in monoamine neurotransmitter modulation. Pharmacological studies have consistently supported Sertraline's efficacy in addressing psychological states associated with neurotransmitter imbalance.

Sertraline's designation as an SSRI means it functions through a targeted, selective mechanism, chemically unrelated to older antidepressant classes. This classification indicates its established role in supporting the central nervous system, positioning it as a clinically recognized tool for providing specialized psychiatric support.

Composition and Physical Form of the Preparation

Serlain is typically manufactured as a single-ingredient product, containing only the active compound Sertraline. The dominant pharmaceutical preparation is the film-coated tablet, designed for safe and measured oral administration. The tablet's base is formed using Sertraline hydrochloride alongside necessary pharmaceutical excipients, resulting in a stable, solid dosage form. The preparation’s purpose is to facilitate the precise delivery of Sertraline into the body, initiating the specific action of binding to presynaptic serotonin transporters (SERT).

The General Purpose of This Antidepressant

The general purpose of Serlain is to support the body’s ability to achieve and maintain a more balanced psychological state by affecting neurochemistry. Its mechanism involves temporary serotonin reuptake inhibition, which increases the concentration of serotonin availability between nerve cells. By sustaining this neurotransmitter modulation, the medication is designed to assist in the stabilization of mood and the alleviation of emotional distress, such as that experienced during periods of generalized anxiety.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Serlain?

Possible Side Effects and Safety Information

The safety profile of Serlain (sertraline) is officially categorized by regulatory agencies based on the frequency and nature of observed adverse reactions. Side effects are often grouped by the System-Organ-Class (SOC) affected, such as gastrointestinal, nervous system, and psychiatric disorders.

Classification Examples of Adverse Reactions
Very Common (≥ 1/10) Nausea, insomnia, dry mouth, diarrhea, ejaculation failure (in males).
Common (≥ 1/100 to < 1/10) Dizziness, tremor, somnolence, fatigue, decreased appetite, increased sweating, decreased libido.

The safety documentation highlights the potential for Serious Adverse Reactions. These include the risk of Serotonin Syndrome (a potentially life-threatening condition), the activation of mania or hypomania, and the potential for severe abnormal bleeding or hemorrhage. Furthermore, regulatory labels note the risk of QTc prolongation and Torsade de Pointes (TdP), which are rare but serious cardiac events, and angle-closure glaucoma.

Time-Related Patterns and Constraints

Safety concerns are noted to be time-dependent. An increased risk of suicidal thoughts and behaviors is officially documented, especially in pediatric and young adult patients, typically occurring during the initial weeks of treatment or following dose adjustments. Abrupt cessation of the medicine is associated with a high incidence of discontinuation syndrome (withdrawal symptoms). Safety restrictions include the formal contraindication of Serlain with Irreversible Monoamine Oxidase Inhibitors (MAOIs) due to the risk of Serotonin Syndrome, and with Pimozide.

Population-Specific Notes

The official labeling includes specific considerations for certain patient populations. Older adults are noted to be at greater risk for hyponatremia (low sodium levels). Caution is required for patients with hepatic impairment as drug clearance is reduced.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the potential manifestations and required emergency actions for Serlain (sertraline) overdose. Overdose may affect the CNS, cardiovascular, and gastrointestinal systems, and aggressive medical treatment is required.

Documented Overdose Manifestations

Clinical signs formally listed in regulatory labeling include somnolence, tremor, agitation, and tachycardia (fast heart rate). Gastrointestinal disturbances such as nausea and vomiting are also documented. Serious and potentially life-threatening outcomes are officially recognized, notably Serotonin Syndrome, seizures, and coma, with reports of QTc prolongation and Torsade de Pointes.

Overdose severity is known to be significantly increased when Sertraline is co-ingested with other drugs and/or alcohol.

Mandated Emergency Action

Regulators mandate that immediate medical attention must be sought for any suspected overdose. Emergency services or a poison control center must be contacted right away.

In a clinical setting, ECG-monitoring is recommended in all ingestions, alongside continuous cardiac and vital sign observation. Management procedures include establishing and maintaining an airway and administering activated charcoal.

Regulatory documents explicitly state that no specific antidote to reverse the effects of sertraline is known, and procedures like dialysis are considered unlikely to be of benefit.

Therapeutic Uses of Serlain

Serlain: Main Therapeutic Uses and Benefits

Serlain (sertraline) is a prescription medication utilized to address a range of mental health conditions. Its primary uses focus on the management of symptoms associated with various disorders.

Quick Facts

  • Addresses: Major depressive disorder
  • Treats: Obsessive-compulsive disorder (OCD)
  • Manages: Panic disorder
  • Relieves: Symptoms of post-traumatic stress disorder (PTSD)
  • Helps control: Social anxiety disorder
  • Mitigates: Premenstrual dysphoric disorder (PMDD) symptoms

Therapeutic Overview

Serlain is indicated for the treatment of major depressive disorder in adults. It is also used to manage obsessive-compulsive disorder (OCD) in adults and in pediatric patients aged 6 years and older. The medication is also utilized to address panic disorder, with or without agoraphobia.

Furthermore, Serlain is prescribed to alleviate symptoms of post-traumatic stress disorder (PTSD) and social anxiety disorder (also known as social phobia). The compound also assists in mitigating the emotional and physical symptoms associated with premenstrual dysphoric disorder (PMDD). The benefits include stabilizing mood, reducing the frequency and intensity of panic attacks, and lessening fear and anxiety in social situations. The continuation of treatment should be regularly evaluated by a healthcare professional.

Eligibility and Restrictions for Use

This section outlines official eligibility and restrictions for Serlain (sertraline) based on regulatory documents.

Populations for whom use is Contraindicated

Classification Rule
Drug-Drug Interaction Concomitant use with irreversible Monoamine Oxidase Inhibitors (MAOIs), including the antibiotic linezolid and intravenous methylene blue. A minimum 14-day washout period is required after stopping an irreversible MAOI before starting Serlain, and a 7-day washout is required after stopping Serlain before starting an MAOI.
Drug-Drug Interaction Concomitant use with pimozide (an antipsychotic).
Clinical State Documented hypersensitivity to sertraline or any of the inactive ingredients.

Populations Requiring Special Consideration or Restricted Use

Classification Rule / Restriction
Age Pediatric patients (under 18 years) are generally not recommended for treatment, with the exception of patients aged 6–17 years for the treatment of Obsessive-Compulsive Disorder (OCD).
Organ Function Patients with hepatic impairment should be treated with caution; a lower or less frequent dosage is recommended.
Comorbid Condition Use should be avoided in patients with unstable epilepsy and in those with untreated anatomically narrow angles (a risk factor for angle-closure glaucoma).
Clinical History Use with caution in patients with a history of mania or hypomania and in those with risk factors for QTc prolongation (heart rhythm disorder risk).

Official documents do not list pregnancy or lactation as absolute contraindications, but specialized safety information is provided in the drug labeling for use during these periods.

What should I know about interactions with other medicines?

The official regulatory profile for Serlain (sertraline) details specific drug-drug, drug-substance, and drug-food interaction constraints. Co-administration is formally contraindicated with several substances due to the risk of severe reactions. This includes all Monoamine Oxidase Inhibitors ( MAOIs), requiring a mandatory 14-day separation period when switching therapies. Other contraindicated agents are Pimozide, due to documented increases in its plasma concentration, and non-selective MAOI agents like Linezolid or intravenous Methylene Blue. The oral solution formulation is specifically contraindicated with Disulfiram.

Pharmacodynamic interactions involve shared biological pathways. Combining Serlain with other serotonergic agents such as Triptans or the herbal product St. John's Wort carries a heightened regulatory warning for the potential of Serotonin Syndrome. Furthermore, co-administration with NSAIDs, anticoagulants, and antiplatelet drugs increases the officially documented risk of bleeding. Serlain acts as an inhibitor of the CYP2D6 enzyme, a pharmacokinetic interaction that increases the systemic exposure of co-administered CYP2D6 substrates. The official labeling notes that taking the tablet with food increases Serlain's maximum plasma concentration ( Cmax), and the use of alcohol is not recommended. In patients with hepatic impairment, clearance of Serlain is reduced, leading to increased drug exposure.

Mechanism of Action

Serotonin Reuptake Inhibition: The Molecular Start

Serlain acts as a selective inhibitor of the Serotonin Transporter ( SERT), a protein located on the presynaptic neuronal membrane. By binding to SERT, the drug blocks the reabsorption of the neurotransmitter serotonin ( 5-HT) from the synaptic cleft back into the neuron. This molecular blockade immediately raises the local concentration of available 5-HT, which is the initial molecular event of the mechanism.

Time-Dependent Neural Adaptation: The Systemic Cascade

The sustained increase in synaptic serotonin initiates a critical, long-term cascade involving the desensitization of inhibitory autoreceptors on the presynaptic neuron. This physiological adjustment enhances overall serotonergic transmission over time, which is associated with the modulation of neural systems responsible for affective signaling and processing.

Secondary and Peripheral Modulation: The Broader Scope

The mechanism extends beyond SERT to include antagonism of the sigma-1 (sigma1) receptor and inhibition of serotonin uptake in platelets. This peripheral action alters the signaling patterns within coagulation-related processes, and the sigma1 interaction contributes to the drug's central profile.

Dosage and Administration Information

How to Use Serlain

Serlain (sertraline) is administered exclusively via the oral route and is typically available as film-coated tablets in strengths such as 25 mg, 50 mg, and 100 mg. The medicine is taken once daily and may be administered either in the morning or the evening. A key administration instruction is that the tablets can be taken with or without food.

Standard Dosing and Adjustment Protocol

Treatment is typically initiated at a low dose, such as 50 mg daily for most indications. However, for conditions like Panic Disorder and Post-Traumatic Stress Disorder (PTSD), the starting dose is often lower at 25 mg daily for the first week. The daily dose is subject to adjustment by a healthcare professional, with any increments, typically 25–50 mg, occurring at intervals of at least one week. The maximum approved daily dose for Serlain is 200 mg.

Administration Contexts

Dose Adjustments for Specific Populations

Patients with known hepatic impairment (liver problems) generally require a reduced starting dose, often half the standard amount, due to decreased clearance. For older adults, treatment is also typically initiated at the lower end of the dosing range. For pediatric patients (ages 6–12) being treated for Obsessive-Compulsive Disorder (OCD), the initial dose is 25 mg daily.

Missed Dose and Discontinuation

If a daily dose is missed, patients should skip the missed dose and resume the schedule with the next dose at the usual time; doubling the next dose is not recommended. When discontinuing treatment, the dose should be gradually reduced over a period of at least one to two weeks, rather than stopping abruptly.

Recent Clinical Evidence

Research evidence / Overview of Studies for Serlain (Sertraline)

Evidence for Use in Major Depressive Disorder and OCD

The clinical evaluation of Serlain for Major Depressive Disorder (MDD) has primarily relied on Randomized Controlled Trials (RCTs) conducted over short periods, typically 6 to 12 weeks. Research examined how symptoms evolved in the observed populations, using standardized scales to track changes in depressive symptom intensity. Continuation studies explored the patterns associated with the return of symptoms (relapse or recurrence) when treatment was sustained. Long-term outcomes are not well characterized, and evidence for functional recovery beyond symptom scores remains limited in many regulatory reports.

For Obsessive-Compulsive Disorder (OCD), Serlain was studied for both short-term observation and long-term maintenance in adults and pediatric patients (children and adolescents). Studies tracked OCD symptom severity and recurrence rates. Research limitations include the observation that the onset of change appears to require more time in OCD trials, and limited information exists for long-term functional outcomes.

Evidence for Use in Anxiety and Trauma-Related Disorders

Serlain was evaluated in trials assessing short-term symptom patterns in Panic Disorder (PD). Studies examined outcomes capturing phases of heightened symptom activity, specifically the frequency of panic attacks. Continuation studies tracked patterns associated with symptom return. For Post-Traumatic Stress Disorder (PTSD), trials primarily involved adults and monitored changes in symptom severity. Evidence reviews sometimes described findings related to patterns of symptom change, but long-term outcomes are not fully established beyond the first few months of observation.

Research Gaps and Areas of Uncertainty

The body of evidence, while substantial for acute treatment, highlights several limitations. Data are still emerging for certain specific populations. The certainty remains low for outcomes over very extended periods (multi-year follow-up) across all indications. The generalizability of results may be limited, as many studies exclude patients with high levels of psychiatric comorbidity. Therefore, the results apply only to the populations studied.

How should Serlain be stored and disposed of?

The official requirements for Serlain (sertraline) storage focus on maintaining stability and safety. Most formulations must be stored at room temperature, specifically between 68 F and 77 F (20 C to 25 C), although some film-coated tablets require no special temperature conditions.

The medicine should be kept in its original container, which must be tightly closed to protect it from excessive heat and moisture. A mandatory requirement across all forms is to keep Serlain out of the sight and reach of children.

For disposal, the primary recommendation is to use a drug take-back program or mail-back envelope. If those are unavailable, the medicine is not on the FDA's flush list and can be thrown in the household trash after mixing it with an undesirable substance, such as used coffee grounds, to deter misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBelgium

Equivalent of Serlain found in:

A-Z Index: